353 related articles for article (PubMed ID: 33374542)
1. Immunocompetent Mouse Models in the Search for Effective Immunotherapy in Glioblastoma.
Wouters R; Bevers S; Riva M; De Smet F; Coosemans A
Cancers (Basel); 2020 Dec; 13(1):. PubMed ID: 33374542
[TBL] [Abstract][Full Text] [Related]
2. Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds.
Asija S; Chatterjee A; Yadav S; Chekuri G; Karulkar A; Jaiswal AK; Goda JS; Purwar R
Int Rev Immunol; 2022; 41(6):582-605. PubMed ID: 35938932
[TBL] [Abstract][Full Text] [Related]
3. Combination immunotherapy strategies for glioblastoma.
Chan HY; Choi J; Jackson C; Lim M
J Neurooncol; 2021 Feb; 151(3):375-391. PubMed ID: 33611705
[TBL] [Abstract][Full Text] [Related]
4. Development of a human glioblastoma model using humanized DRAG mice for immunotherapy.
Srivastava R; Labani-Motlagh A; Chen A; Yang F; Ansari D; Patel S; Ji H; Trasti S; Dodda M; Patel Y; Zou H; Hu B; Yi G
bioRxiv; 2023 Feb; ():. PubMed ID: 36824969
[TBL] [Abstract][Full Text] [Related]
5. Molecular Heterogeneity and Immunosuppressive Microenvironment in Glioblastoma.
DeCordova S; Shastri A; Tsolaki AG; Yasmin H; Klein L; Singh SK; Kishore U
Front Immunol; 2020; 11():1402. PubMed ID: 32765498
[TBL] [Abstract][Full Text] [Related]
6. γδ T cells as a potential therapeutic agent for glioblastoma.
Kang I; Kim Y; Lee HK
Front Immunol; 2023; 14():1273986. PubMed ID: 37928546
[TBL] [Abstract][Full Text] [Related]
7. Glioblastoma Organoids: Pre-Clinical Applications and Challenges in the Context of Immunotherapy.
Klein E; Hau AC; Oudin A; Golebiewska A; Niclou SP
Front Oncol; 2020; 10():604121. PubMed ID: 33364198
[TBL] [Abstract][Full Text] [Related]
8. Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment.
Pearson JRD; Cuzzubbo S; McArthur S; Durrant LG; Adhikaree J; Tinsley CJ; Pockley AG; McArdle SEB
Front Immunol; 2020; 11():582106. PubMed ID: 33178210
[TBL] [Abstract][Full Text] [Related]
9. Extrinsic factors associated with the response to immunotherapy in glioblastoma.
Bi H; Zhang C
Cancer Lett; 2021 Jul; 511():47-55. PubMed ID: 33933551
[TBL] [Abstract][Full Text] [Related]
10. The CNS and the Brain Tumor Microenvironment: Implications for Glioblastoma Immunotherapy.
Desland FA; Hormigo A
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33027976
[TBL] [Abstract][Full Text] [Related]
11. Syngeneic murine glioblastoma models: reactionary immune changes and immunotherapy intervention outcomes.
Letchuman V; Ampie L; Shah AH; Brown DA; Heiss JD; Chittiboina P
Neurosurg Focus; 2022 Feb; 52(2):E5. PubMed ID: 35104794
[TBL] [Abstract][Full Text] [Related]
12. KR158 spheres harboring slow-cycling cells recapitulate GBM features in an immunocompetent system.
Chakraborty A; Yang C; Kresak JL; Silver A; Feier D; Tian G; Andrews M; Sobanjo OO; Hodge ED; Engelbart MK; Huang J; Harrison JK; Sarkisian MR; Mitchell DA; Deleyrolle LP
bioRxiv; 2024 Jan; ():. PubMed ID: 38501121
[TBL] [Abstract][Full Text] [Related]
13. Tumor Niches: Perspectives for Targeted Therapies in Glioblastoma.
Srivastava R; Dodda M; Zou H; Li X; Hu B
Antioxid Redox Signal; 2023 Nov; 39(13-15):904-922. PubMed ID: 37166370
[No Abstract] [Full Text] [Related]
14. The Many Facets of Therapy Resistance and Tumor Recurrence in Glioblastoma.
Goenka A; Tiek D; Song X; Huang T; Hu B; Cheng SY
Cells; 2021 Feb; 10(3):. PubMed ID: 33668200
[TBL] [Abstract][Full Text] [Related]
15. Identification, validation and biological characterisation of novel glioblastoma tumour microenvironment subtypes: implications for precision immunotherapy.
White K; Connor K; Meylan M; Bougoüin A; Salvucci M; Bielle F; O'Farrell AC; Sweeney K; Weng L; Bergers G; Dicker P; Ashley DM; Lipp ES; Low JT; Zhao J; Wen P; Prins R; Verreault M; Idbaih A; Biswas A; Prehn JHM; Lambrechts D; Arijs I; Lodi F; Dilcan G; Lamfers M; Leenstra S; Fabro F; Ntafoulis I; Kros JM; Cryan J; Brett F; Quissac E; Beausang A; MacNally S; O'Halloran P; Clerkin J; Bacon O; Kremer A; Chi Yen RT; Varn FS; Verhaak RGW; Sautès-Fridman C; Fridman WH; Byrne AT
Ann Oncol; 2023 Mar; 34(3):300-314. PubMed ID: 36494005
[TBL] [Abstract][Full Text] [Related]
16. The immune cell landscape of glioblastoma patients highlights a myeloid-enriched and immune suppressed microenvironment compared to metastatic brain tumors.
Musca B; Russo MG; Tushe A; Magri S; Battaggia G; Pinton L; Bonaudo C; Della Puppa A; Mandruzzato S
Front Immunol; 2023; 14():1236824. PubMed ID: 37936683
[TBL] [Abstract][Full Text] [Related]
17. Intravital imaging reveals synergistic effect of CAR T-cells and radiation therapy in a preclinical immunocompetent glioblastoma model.
Murty S; Haile ST; Beinat C; Aalipour A; Alam IS; Murty T; Shaffer TM; Patel CB; Graves EE; Mackall CL; Gambhir SS
Oncoimmunology; 2020 May; 9(1):1757360. PubMed ID: 32923113
[TBL] [Abstract][Full Text] [Related]
18. Advances in Nanotechnology-Based Immunotherapy for Glioblastoma.
Tang L; Zhang M; Liu C
Front Immunol; 2022; 13():882257. PubMed ID: 35651605
[TBL] [Abstract][Full Text] [Related]
19. Tumor-associated microglia and macrophages in glioblastoma: From basic insights to therapeutic opportunities.
Wang G; Zhong K; Wang Z; Zhang Z; Tang X; Tong A; Zhou L
Front Immunol; 2022; 13():964898. PubMed ID: 35967394
[TBL] [Abstract][Full Text] [Related]
20. The N
Zhao R; Li B; Zhang S; He Z; Pan Z; Guo Q; Qiu W; Qi Y; Zhao S; Wang S; Chen Z; Zhang P; Guo X; Xue H; Li G
Front Immunol; 2021; 12():653711. PubMed ID: 34354698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
